The FDA has approved the first nociception monitoring system for surgical patients in the United States.1

The PMD-200 patient monitor from Medasense Biometrics Ltd (Ramat Gan, Israel) with nociception level (NOL) index technology measures pain levels in anesthetized patients. It uses artificial intelligence (AI) algorithms and a proprietary multiparametric composite of autonomic signals to gauge physiologic responses to pain. The system is designed to help control pain levels and avoid overmedication and its associated complications.

Medasense's PMD-200 with NOL technology aims to help anesthesiologists provide real-time, personalized pain management in the operating room.

According to a press release issued by Medasense, "A recent publication showed that the odds of suffering severe post-operative pain are six times lower with NOL monitoring." The press release cited an article by van der Wal et al, among others.2

References